d3 bio presents kras pipeline updates at aacr 2026 elisrasib d3s 001 a next generation kras g12c inhibitor shows strong phase 2 efficacy across multiple tumor types

CRISISLEX_C03_WELLBEING_HEALTHTAX_FNCACT_CHIEF_EXECUTIVE_OFFICERTAX_FNCACT_EXECUTIVETAX_DISEASE_HYPOKALEMIA

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.